Development and consensus testing of quality indicators for geriatric pharmacotherapy in primary care using a modified Delphi study

被引:0
作者
Noriko Sato
Kenji Fujita
Kazuki Kushida
Timothy F. Chen
机构
[1] The University of Sydney,School of Pharmacy, Faculty of Medicine and Health
[2] The University of Sydney,Departments of Clinical Pharmacology and Aged Care, Faculty of Medicine and Health
[3] Kolling Institute,Faculty of Pharmacy
[4] Showa Pharmaceutical University,undefined
来源
International Journal of Clinical Pharmacy | 2022年 / 44卷
关键词
Community pharmacy; Geriatric pharmacotherapy; Older people; Primary care; Quality indicators;
D O I
暂无
中图分类号
学科分类号
摘要
Background Polypharmacy is associated with an increased risk of adverse drug events in older people. Although national guidance on geriatric pharmacotherapy exists in Japan, tools to routinely monitor the quality of care provided by community pharmacists are lacking. Aim To develop a set of quality indicators (QIs) to measure the quality of care provided by community pharmacists in improving geriatric pharmacotherapy in primary care in Japan, using a modified Delphi study. Method The development of QIs for the Japanese community pharmacy context followed a two–step process: national guidance review and consensus testing using a modified Delphi study. The latter involved two rounds of rating with a face–to–face meeting between the rounds. Ten experts in geriatric pharmacotherapy in primary care were recruited for the panel discussion. QIs were mapped to three key taxonomies and frameworks: the Anatomical Therapeutic Chemical (ATC) classification system, problems and causes of drug–related problems (DRPs) taxonomy and Donabedian’s framework. Results A total of 134 QIs for geriatric pharmacotherapy were developed. This QI set included 111 medicine specific indicators, covering medicines in 243 third–level ATC classifications. QIs were classified into the problem of treatment safety (80%) and causes of drug selection (38%) based on validated classification for DRPs. In Donabedian's framework, most QIs (82%) were process indicators. There were no structure indicators. Conclusion A set of 134 QIs for geriatric pharmacotherapy was rigorously developed. Measurement properties of these QIs will be evaluated for feasibility, applicability, room for improvement, sensitivity to change, predictive validity, acceptability and implementation issues in a subsequent study.
引用
收藏
页码:517 / 538
页数:21
相关论文
共 111 条
[1]  
Page AT(2019)Polypharmacy among older Australians, 2006–2017: a population–based study Med J Aust 211 71-75
[2]  
Falster MO(2018)Trends in polypharmacy in Japan: a nationwide retrospective study J Am Geriatr Soc 66 2267-2273
[3]  
Litchfield M(2021)Deprescribing in the older patient: a narrative review of challenges and solutions Int J Gen Med 14 3793-3807
[4]  
Onoue H(2019)Prevalence of hospitalisation caused by adverse drug reactions at an internal medicine ward of a single centre in Japan: a cross–sectional study BMJ Open 9 e030515-209
[5]  
Koyama T(2016)Improving the appropriateness of prescribing in older patients: a systematic review and meta–analysis of pharmacists' interventions in secondary care Age Ageing 45 201-187
[6]  
Zamami Y(2014)Pharmacist–led interventions to reduce unplanned admissions for older people: a systematic review and meta–analysis of randomised controlled trials Age Ageing 43 174-543
[7]  
Wu H(1990)Opportunities and responsibilities in pharmaceutical care Am J Health Syst Pharm 47 533-555
[8]  
Kouladjian O'Donnell L(2014)Pharmaceutical Care: the PCNE definition 2013 Int J Clin Pharm 36 544-533
[9]  
Fujita K(2021)Ghent older people’s prescriptions community pharmacy screening (GheOP3S)–tool version 2: update of a tool to detect drug–related problems in older people in primary Care Drugs Aging 38 523-2724
[10]  
Komagamine J(1960)Updating the beers criteria for potentially inappropriate medication use in older adults: results of a us consensus panel of experts Arch Intern Med 2003 2716-1001